GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (FRA:45O) » Definitions » Institutional Ownership

Orgenesis (FRA:45O) Institutional Ownership : 5.10% (As of Sep. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Orgenesis Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Orgenesis's institutional ownership is 5.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Orgenesis's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Orgenesis's Float Percentage Of Total Shares Outstanding is 88.14%.


Orgenesis Institutional Ownership Historical Data

The historical data trend for Orgenesis's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Institutional Ownership Chart

Orgenesis Historical Data

The historical data trend for Orgenesis can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 7.52 7.50 5.72 5.50 5.49 5.49 5.49 5.18 5.12 5.10

Orgenesis Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Orgenesis Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Orgenesis Headlines

No Headlines